Empagliflozin

From Proteopedia

Jump to: navigation, search

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. See also Empagliflozin.

Empagliflozin is an inhibitor of the Sodium/glucose cotransporter (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine.[1][2][3]

Human SGLT2-MAP17 complex bound with empagliflozin (7vsi).

Empagliflozin binding site.

See also:

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. ↑ Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008 Sep;14(6):782-90. PMID:18996802 doi:10.4158/EP.14.6.782
  2. ↑ Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. PMID:19892839 doi:10.1210/jc.2009-0473
  3. ↑ Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009 Mar;25(3):671-81. PMID:19232040 doi:10.1185/03007990802710422

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Retrieved from "http://proteopedia.org/wiki/index.php/Empagliflozin"
Personal tools